99%+ Purity
COA Included
Sealed Vials
Mazdutide
GLP-1/Glucagon dual agonist for metabolic optimization
GLP-1 + glucagon agonist
Key Benefits
- Dual GLP-1 and glucagon receptor targeting
- May support glucose-dependent insulin optimization
- Potential enhancement of energy expenditure
- Research suggests improved satiety signaling
- May promote balanced metabolic function
- Extended half-life for sustained activity
- Glucose-dependent mechanism reduces hypoglycemia risk
Burn Fat While Staying Metabolically Healthy
Most fat loss approaches crash your metabolism and leave you hungrier than before. Mazdutide works differently—it activates your body's natural fat-burning pathways while keeping your blood sugar stable and appetite controlled. You get sustainable fat loss without the metabolic damage that makes most people regain everything they lost.
GLP-1 and glucagon receptor pathways / Glucose homeostasis and energy expenditure optimization
About Mazdutide
Mazdutide is a dual-action peptide that simultaneously targets both GLP-1 and glucagon receptors to optimize metabolic function. It enhances insulin sensitivity and appetite control through GLP-1 activation while promoting energy expenditure and fat oxidation via glucagon receptor engagement. This dual mechanism creates balanced metabolic effects that support both glucose management and sustainable body composition improvements.
Who It's For
Ideal for individuals seeking comprehensive metabolic optimization who want to address both body composition and metabolic health simultaneously. The glucose-dependent mechanism makes it suitable for those concerned about blood sugar stability during fat loss phases. Works well as part of longer-term metabolic restoration protocols where sustainable results matter more than rapid but temporary changes.
Research Background
Mazdutide represents an innovative approach in metabolic therapeutics by simultaneously targeting two crucial hormone pathways involved in glucose and energy homeostasis. The GLP-1 pathway primarily handles post-meal blood sugar control by enhancing insulin release when glucose levels are elevated, while also promoting satiety and slowing stomach emptying to reduce food intake. The glucagon pathway traditionally stimulates the liver to produce glucose when energy is needed, but in this therapeutic context, it may enhance energy burning and fat metabolism. This dual-action design aims to address multiple aspects of metabolic dysfunction simultaneously.
Research focus areas include: 1) Optimizing the balance between GLP-1 and glucagon activities to maximize therapeutic benefits while minimizing side effects, 2) Understanding how the compound affects different patient populations with varying degrees of insulin resistance and obesity, and 3) Determining optimal dosing strategies and treatment duration for sustainable metabolic improvements. The primary goal is developing a treatment that not only manages blood sugar effectively but also promotes meaningful weight loss and overall metabolic health improvement in patients with type 2 diabetes and obesity.
Dosing Protocol
| Level | Dose | |
|---|---|---|
Beginner | 2 mg/wk | |
Intermediate | 4 mg/wk | |
Advanced | 6-8 mg/wk | |
Maximum | 10-12 mg/wk |
Select a dosing level and click Calculate to plan your protocol.
Vials Required
5
48.0 mg needed ÷ 10 per vial
Total Investment
$650
$130.00 per vial
Per Dose
0.40 mL
40 units on U-100 syringe
Doses per Vial
2
10 ÷ 4.00 mg/dose
* Calculations based on standard reconstitution protocols. Consult research guidelines for specific applications.
Compliance & Disclaimer
This product is intended for laboratory research purposes only. Not for human consumption. All products are sold with the understanding that the purchaser will comply with all applicable local, state, and federal laws regarding the purchase and use of research chemicals. Certificate of Analysis available upon request.
Mazdutide
$130.00